AVNS · As filed with the SEC
Avanos Medical balance sheet, by fiscal year
The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 | FY2020 Dec 31, 2020 | FY2019 Dec 31, 2019 | FY2018 Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | 89,800,000 | 107,700,000 | 87,700,000 | 127,700,000 | 118,500,000 | 111,500,000 | 205,300,000 | 384,500,000 |
| Accounts receivable, net of allowances | — | — | — | — | — | — | 163,800,000 | 150,500,000 |
| Accounts receivable, net of allowances | 103,800,000 | 132,800,000 | 142,800,000 | 167,900,000 | 118,200,000 | 108,600,000 | — | — |
| Income tax receivable | — | — | — | — | 13,000,000 | 59,300,000 | — | — |
| Inventories | 148,000,000 | 138,800,000 | 163,200,000 | 190,300,000 | 150,300,000 | 168,900,000 | 145,900,000 | 121,400,000 |
| Prepaid and other current assets | 13,800,000 | 14,100,000 | 28,800,000 | 13,900,000 | 18,600,000 | 18,900,000 | 23,500,000 | 57,200,000 |
| Assets held for sale | — | 0 | 64,500,000 | — | — | — | — | 0 |
| Total Current Assets | 355,400,000 | 393,400,000 | 487,000,000 | 499,800,000 | 418,600,000 | 467,200,000 | 538,500,000 | 713,600,000 |
| Property, Plant and Equipment, net | 113,400,000 | 110,700,000 | 117,200,000 | 163,900,000 | 168,100,000 | 175,300,000 | 184,500,000 | 154,100,000 |
| Operating Lease Right-of-Use Assets | 27,600,000 | 34,100,000 | 26,800,000 | 30,600,000 | 38,600,000 | 48,300,000 | 64,000,000 | — |
| Goodwill | 394,900,000 | 455,600,000 | 796,100,000 | 819,400,000 | 801,600,000 | 802,500,000 | 800,900,000 | 783,600,000 |
| Other Intangible Assets, net | 117,800,000 | 112,300,000 | 239,500,000 | 251,000,000 | 141,200,000 | 157,700,000 | 184,300,000 | 168,200,000 |
| Deferred Tax Assets | 33,100,000 | 24,900,000 | 6,500,000 | 4,600,000 | 10,000,000 | 10,000,000 | 16,100,000 | 6,300,000 |
| Other Assets | 31,500,000 | 23,200,000 | 19,300,000 | 17,600,000 | 16,500,000 | 11,800,000 | 11,300,000 | 7,600,000 |
| TOTAL ASSETS | 1,073,700,000 | 1,154,200,000 | 1,692,400,000 | 1,786,900,000 | 1,594,600,000 | 1,672,800,000 | 1,799,600,000 | 1,833,400,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities | ||||||||
| Current portion of long-term debt | 10,200,000 | 9,400,000 | 8,600,000 | 6,200,000 | — | — | — | 0 |
| Current portion of operating lease liabilities | 8,200,000 | 10,900,000 | 12,800,000 | 12,800,000 | 14,700,000 | 15,500,000 | 14,700,000 | — |
| Trade accounts payable | 55,500,000 | 54,300,000 | 56,300,000 | 67,900,000 | 56,400,000 | 67,600,000 | 83,000,000 | 169,900,000 |
| Accrued expenses | 91,300,000 | 91,300,000 | 93,200,000 | 98,900,000 | 68,100,000 | 83,200,000 | 114,800,000 | 94,400,000 |
| Liabilities held for sale | — | 0 | 63,700,000 | — | — | — | — | 0 |
| Total Current Liabilities | 165,200,000 | 165,900,000 | 234,600,000 | 185,800,000 | 139,200,000 | 166,300,000 | 212,500,000 | 264,300,000 |
| Long-Term Debt | — | — | — | 226,300,000 | — | — | 248,100,000 | 247,700,000 |
| Long-Term Debt | 90,300,000 | 125,300,000 | 159,400,000 | — | 130,000,000 | 180,000,000 | — | — |
| Operating Lease Liabilities | 20,400,000 | 24,600,000 | 28,300,000 | 34,700,000 | 42,800,000 | 53,300,000 | 62,600,000 | — |
| Deferred Tax Liabilities | 6,100,000 | 5,500,000 | 23,800,000 | 25,400,000 | 9,600,000 | 5,700,000 | 0 | 4,400,000 |
| Other Long-Term Liabilities | 13,500,000 | 4,400,000 | 10,000,000 | 23,500,000 | 9,100,000 | 11,000,000 | 11,200,000 | 19,800,000 |
| Total Liabilities | 295,500,000 | 325,700,000 | 456,100,000 | 495,700,000 | 330,700,000 | 416,300,000 | 534,400,000 | 536,200,000 |
| Stockholders’ Equity | ||||||||
| Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common stock - $0.01 par value - authorized 300,000,000 shares, 46,456,462 outstanding at December 31, 2025 and 45,962,627 outstanding at December 31, 2024 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 |
| Additional paid-in capital | 1,691,900,000 | 1,678,600,000 | 1,663,600,000 | 1,646,400,000 | 1,628,800,000 | 1,609,400,000 | 1,593,900,000 | 1,578,100,000 |
| Accumulated deficit | (779,900,000) | (707,000,000) | (314,900,000) | (253,100,000) | (310,300,000) | (315,500,000) | (288,300,000) | (242,400,000) |
| Treasury stock | — | — | — | — | (21,300,000) | (9,800,000) | (8,900,000) | (5,300,000) |
| Treasury stock | (102,300,000) | (99,000,000) | (85,900,000) | (66,800,000) | — | — | — | — |
| Accumulated other comprehensive loss | (32,000,000) | (44,600,000) | (27,000,000) | (35,800,000) | (33,800,000) | (28,100,000) | (32,000,000) | (33,700,000) |
| Total Stockholders’ Equity | 778,200,000 | 828,500,000 | 1,236,300,000 | 1,291,200,000 | 1,263,900,000 | 1,256,500,000 | 1,265,200,000 | 1,297,200,000 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 1,073,700,000 | 1,154,200,000 | 1,692,400,000 | 1,786,900,000 | 1,594,600,000 | 1,672,800,000 | 1,799,600,000 | 1,833,400,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.